Nasal Polyps
Clinical Snapshot
Chronic rhinosinusitis with nasal polyps (CRSwNP) is the phenotype of chronic rhinosinusitis defined by bilateral, endoscopically visible, translucent polypoid growths arising from the sinonasal mucosa — most often the middle meatus and ethmoid sinuses — in a patient who also meets the general 12-week chronic rhinosinusitis (CRS) symptom criteria.[1] This chapter is a deliberately focused extension of the Chronic Sinusitis chapter, not a substitute for it: that chapter carries the full shared CRS diagnostic framework, the 4 cardinal symptoms, and the CRS-without-polyps (CRSsNP) content that is not repeated here. What follows is specific to the polyp phenotype — endoscopic recognition and objective grading of the polyps themselves, the tightly linked aspirin-exacerbated respiratory disease (AERD, historically Samter's triad) subgroup, and the escalation ladder through biologic therapy and surgery that has no real CRSsNP analogue.[2]
Roughly 20-33% of adults with CRS have the polyp phenotype, with population prevalence of CRSwNP itself estimated around 2-4%, rising through midlife and more common in men.[1] CRSwNP is now understood as a predominantly type 2 (eosinophilic) inflammatory disease — driven by interleukin (IL)-4, IL-5, and IL-13 — rather than a purely mechanical or infectious problem of the sinuses; this endotype understanding is precisely what has made targeted biologic therapy possible and is the organizing idea behind the treatment ladder in this chapter.[1][3]
Recognize the Condition
The classic presentation
Unlike CRSsNP, where facial pain/pressure and purulent discharge often dominate, CRSwNP is characteristically a disease of progressive, often severe nasal obstruction and hyposmia-to-anosmia. Patients frequently describe both nostrils feeling permanently blocked, unresponsive to decongestants, together with a gradually worsening or complete loss of smell that can be the presenting complaint even before obstruction becomes prominent.[1] Rhinorrhea (anterior and/or posterior) is common; facial pain/pressure, when present, tends to be milder and less localized than in CRSsNP, and its absence should not be used to argue against the diagnosis.[1] Snoring and mouth breathing, especially at night, are common secondary complaints, and depression/anxiety symptoms are more prevalent with more severe olfactory loss — smell loss is a genuine, often underestimated quality-of-life burden, not a trivial complaint.[3]
Endoscopic recognition and grading
Polyps are avascular, edematous, typically pale grey-yellow to translucent and glistening on nasal endoscopy — a genuinely distinct appearance from the erythematous, vascular turbinate mucosa of allergic or vasomotor rhinitis, a useful bedside discriminator wherever endoscopy is available.[1] Nasal endoscopy, not anterior rhinoscopy, is required to reliably confirm or exclude CRSwNP: polyps confined to the middle meatus or posterior nasal cavity are easily missed on anterior rhinoscopy alone, and a patient labelled CRSsNP on rhinoscopy alone may in fact have polyps only visible on endoscopy.[1][2]
| Nasal Polyp Score (0-4 per side, summed to a total of 0-8) | Endoscopic appearance |
|---|---|
| 0 | No polyps |
| 1 | Small polyps confined to the middle meatus, not reaching below the inferior border of the middle turbinate |
| 2 | Polyps extending below the inferior border of the middle turbinate |
| 3 | Large polyps extending to the lower border of the inferior turbinate, or medially to the nasal septum |
| 4 | Large polyps causing complete obstruction of the inferior nasal cavity |
[4] A bilateral total Nasal Polyp Score (NPS) is the objective measure used throughout this chapter to track disease burden and treatment response — the same score used as a coprimary endoscopic endpoint in the major biologic trials cited in Choose Initial Treatment.[5][6][7]
Clinical pearl — ask about NSAID/aspirin reactions in every CRSwNP patient with asthma
The triad of CRSwNP, asthma, and aspirin/NSAID hypersensitivity — historically Samter's triad, now aspirin-exacerbated respiratory disease (AERD) — affects roughly 0.3-0.9% of the general population, but 10-20% of people with asthma and up to 30-40% of people with both asthma and nasal polyposis.[8] This is a genuinely pharmacist-relevant screening question: a community pharmacist filling a first ibuprofen- or ASA-containing OTC purchase for a patient already known to have polyps and asthma is realistically well positioned to ask it. Reactions in AERD are respiratory (nasal congestion/rhinorrhea and/or bronchospasm), typically within 30-180 minutes of ingestion, and are not IgE-mediated — they reflect a specific derangement of arachidonic acid metabolism (excess cysteinyl-leukotriene production once cyclooxygenase-1 is inhibited), which is why the reaction is a class effect across essentially all COX-1-inhibiting NSAIDs rather than a single-drug allergy, and why acetaminophen and COX-2-selective agents behave differently (see Special Populations).[9] Polyps and asthma in AERD both tend to be more severe, more likely to recur after surgery, and more treatment-refractory than in aspirin-tolerant CRSwNP — recognizing AERD changes the treatment plan, not only the safety counseling.[8]
Risk Factors
- Asthma — especially adult- or late-onset asthma; the CRSwNP-asthma relationship is bidirectional, and poorly controlled polyps can worsen asthma control and vice versa.
- Aspirin-exacerbated respiratory disease (AERD/Samter's triad) — see Recognize the Condition; ask specifically, do not wait for the patient to volunteer it.
- Allergic and non-allergic (eosinophilic) rhinitis, and atopic disease generally.
- Allergic fungal rhinosinusitis (AFRS) — a distinct, often asymmetric or unilateral-dominant, more aggressive subtype with allergic mucin and fungal hyphae on pathology; co-managed with ENT and treated surgically with adjunctive corticosteroid therapy, not systemic antifungal pharmacotherapy.
- Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) — consider when polyps and asthma coexist with marked peripheral eosinophilia and systemic/vasculitic features; a distinct disease needing rheumatology/immunology co-management, not simply more aggressive CRSwNP therapy.
- Cystic fibrosis — a mandatory consideration in a child or young adult with nasal polyps (see Red Flags & Refer and Special Populations).
- Primary ciliary dyskinesia.
- Male sex and older age through midlife — epidemiologic associations, though CRSwNP occurs across the age and sex spectrum.
- Family history of nasal polyposis — a modest but real genetic clustering has been observed.
Red Flags & Refer
Any of the following changes the plan from routine CRSwNP management to urgent or specialist-directed evaluation:
- A unilateral polyp, or markedly asymmetric bilateral polyps — CRSwNP is a bilateral disease; a genuinely unilateral polyp needs endoscopic biopsy to exclude an inverted papilloma or a frank sinonasal malignancy, not a routine medical trial.
- Nasal polyps in a child under about 12 years old — genuinely uncommon outside of cystic fibrosis; refer for sweat chloride/CFTR testing rather than treating as adult-pattern CRSwNP (see Special Populations).
- Antrochoanal polyp — a single, large polyp arising from the maxillary sinus and extending posteriorly toward the choana, more common in children and young adults; typically needs surgical removal rather than medical therapy, and its unilateral, solitary appearance should not be mistaken for typical bilateral CRSwNP.
- Unexplained or recurrent epistaxis, especially unilateral.
- Visual change, diplopia, proptosis, or periorbital swelling/erythema.
- A rapidly enlarging polyp, or one with an atypical appearance (fleshy, friable, vascular, ulcerated, or pigmented) rather than the typical pale, glistening, avascular look.
- Suspected EGPA — polyps/asthma with marked peripheral eosinophilia and systemic vasculitic features (mononeuritis multiplex, palpable purpura, new renal or cardiac involvement).
- Suspected allergic fungal rhinosinusitis with orbital or intracranial extension on imaging.
Refer to ENT (routine, not urgent) for: any newly confirmed CRSwNP, for baseline endoscopic staging; inadequate response to an adequate intranasal-corticosteroid-and-saline trial; any patient being considered for biologic therapy or surgery; suspected or confirmed AERD needing aspirin desensitization; and any red flag above that does not need same-day evaluation.
Assessment & Diagnosis
Confirming the phenotype
CRSwNP is diagnosed the same way as CRS generally (see the Chronic Sinusitis chapter) plus one additional, defining requirement: bilateral polyps visualized on nasal endoscopy.[1] Anterior rhinoscopy alone is not sufficient to exclude polyps (see Recognize the Condition); where endoscopy is unavailable, CT of the sinuses showing bilateral polypoid soft-tissue disease is a reasonable alternative, though it does not substitute for endoscopy's ability to directly grade and track polyps over time.[1]
Type 2 endotype workup — supports biologic candidacy, does not gate initial therapy
A peripheral eosinophil count and total serum IgE are reasonable supportive tests once CRSwNP is confirmed — most CRSwNP is type 2/eosinophilic-driven, and eosinophilia supports that endotype and later factors into biologic selection (mepolizumab in particular targets IL-5/eosinophils directly) — but a normal count does not exclude CRSwNP or a type 2 driver, and this testing is not required to start first-line intranasal-corticosteroid/saline therapy.[3] Skin-prick or serum-specific IgE allergy testing is reasonable where an allergic component is suspected clinically.
Screen for AERD at diagnosis, not only once it becomes a problem
Take a specific, structured history of any prior reaction to aspirin or another NSAID in every CRSwNP patient, especially with comorbid asthma (see Recognize the Condition). Where the history is genuinely unclear and the distinction would change management — for example, before considering aspirin desensitization — a supervised oral aspirin challenge in a monitored allergy/immunology setting is the diagnostic gold standard; this is not a test performed in primary care or community pharmacy.[9]
Differential diagnosis specific to the polyp phenotype
| Category | Distinguishing features |
|---|---|
| Inverted papilloma / sinonasal malignancy | Unilateral, often firm, friable, or vascular rather than the typical pale glistening polyp; needs biopsy, not a medical trial (see Red Flags & Refer). |
| Antrochoanal polyp | Single, unilateral, arises from the maxillary sinus; more common in children/young adults; surgical, not medical, management. |
| Allergic fungal rhinosinusitis | Often unilateral-dominant or asymmetric, expansile disease with characteristic allergic mucin and fungal hyphae on pathology, and elevated fungal-specific IgE; surgical debridement plus adjunctive corticosteroid is the core therapy, not antifungal pharmacotherapy. |
| Eosinophilic granulomatosis with polyangiitis (EGPA) | Marked peripheral eosinophilia with systemic/vasculitic features beyond the sinonasal tract; needs rheumatology/immunology co-management. |
| Cystic fibrosis / primary ciliary dyskinesia | Consider in a child or young adult, especially with bronchiectasis or a history of neonatal respiratory distress (see Special Populations). |
| Nasal turbinate hypertrophy / allergic rhinitis | Erythematous, vascular, non-polypoid mucosa on endoscopy; smell is usually less severely affected than in CRSwNP. |
Treatment Targets
- Reduce polyp burden and restore nasal patency, tracked objectively with serial Nasal Polyp Score grading.
- Restore or preserve sense of smell where possible — the target hardest to fully achieve, since established anosmia does not always completely reverse even with effective therapy; set this expectation honestly.
- Control comorbid asthma, treating CRSwNP and asthma as a single "united airway" problem rather than two independent conditions.
- Identify and specifically manage AERD, including safe long-term NSAID/aspirin avoidance or definitive desensitization.
- Minimize the number of oral corticosteroid courses and, once surgery has been used, minimize repeat operations — both biologic therapy and a well-run medical regimen exist specifically to reduce reliance on repeated courses and repeated surgery.
- Reserve biologic therapy and surgery for patients who genuinely meet defined eligibility criteria (see Choose Initial Treatment), not as a default early escalation.
- Identify and refer red-flag presentations rather than treating them as routine CRSwNP.
Choose Initial Treatment
1st line High-dose intranasal corticosteroid plus saline irrigation
Combine daily high-volume saline irrigation with a high-dose intranasal corticosteroid, continued for a genuine 8-12 week trial before judging response — the same backbone therapy as CRS generally (see the Chronic Sinusitis chapter), committed to here at a genuinely adequate dose and for the full trial period given how directly polyp size relates to intranasal corticosteroid dose.[1]
Technique pearl specific to polyps where standard once- or twice-daily spray dosing is inadequate, ENT may direct an intensified regimen — for example, the same budesonide-in-saline rinse approach used in the Chronic Sinusitis chapter — to increase topical deposition directly on the polyps themselves; a specialist-directed intensification, not a default starting regimen.[1]
Short oral corticosteroid course
A short course of oral corticosteroid meaningfully reduces polyp size and improves obstruction/smell in the short term, and is commonly used either as a therapeutic trial after an inadequate response to topical therapy, or specifically to shrink polyps and improve surgical access before endoscopic sinus surgery.[1] Use a short, tapering course (see Drug Tables) — cumulative systemic corticosteroid exposure across repeated courses carries real long-term risk (see Common Errors to Avoid and Special Populations), so a repeated need for oral corticosteroids is a signal to move to biologic therapy or surgery, not a sustainable long-term strategy on its own.[1][3]
Refer for aspirin desensitization under allergy/immunology supervision — a defined, effective option specifically for this subgroup that reduces polyp recurrence and improves both sinus and asthma control, not a routine CRSwNP therapy for aspirin-tolerant patients (see Special Populations for the protocol and Drug Tables for maintenance dosing).[9][8]
Biologic therapy — the Canadian eligibility framework
Biologic therapy dupilumab, omalizumab, or mepolizumab — each Health Canada-approved as add-on therapy to an intranasal corticosteroid for adults with severe CRSwNP inadequately controlled by standard therapy.[5][6][7] The Canadian Rhinology Working Group's consensus statement frames eligibility around 2 core requirements rather than a single numeric cutoff: (1) objectively and subjectively confirmed CRSwNP on validated endoscopy grading and a validated symptom tool such as SNOT-22, and (2) the patient has already undergone adequate sinus surgery and failed an appropriate subsequent medical therapy trial — or, for a patient unfit for surgery, has failed appropriate medical therapy alone.[2] Unlike some biologic-eligibility frameworks elsewhere, comorbid asthma or another type 2 condition is not required to qualify a CRSwNP patient for biologic therapy in this Canadian framework.[2] The complementary international EPOS/EUFOREA framework is often used alongside it: uncontrolled disease despite appropriate surgery and medical therapy, meeting at least 3 of 5 criteria — evidence of type 2 inflammation, a regular need for systemic corticosteroids or a contraindication to them, significantly impaired quality of life, significant loss of smell, and comorbid asthma.[3] Response is judged on both subjective symptom improvement and objective endoscopic (preferred) or CT improvement, formally reassessed at 16 weeks and again at 1 year.[2]
A reasonable and effective alternative — or complementary option — to biologic therapy for medically refractory CRSwNP: it restores sinus ventilation/drainage, allows direct polypectomy, and improves surgical access for topical therapy afterward, but is not curative on its own. Polyp recurrence after surgery is common — reported at roughly 40% by 18 months, and higher still in AERD — which is exactly why ongoing saline/intranasal-corticosteroid maintenance, not a one-time operation, remains the plan after FESS, and why some patients now use biologic therapy alongside surgery rather than choosing one over the other.[10][3]
The choice between biologic therapy and surgery for a given patient is individualized — comorbid asthma severity and AERD status, extent and location of disease, patient preference regarding an ongoing injectable versus a one-time (but potentially repeated) operation, surgical risk, and drug cost/access all reasonably factor in; the two approaches are not mutually exclusive.[11]
Non-Pharmacologic Treatment
- High-volume saline irrigation — the same daily, large-volume technique described in the Chronic Sinusitis chapter; a small-volume nebulized spray is not an equivalent substitute.
- Smoking cessation and avoidance of known irritant/allergen triggers.
- Optimize comorbid asthma control — treat CRSwNP and asthma as a single "united airway," since poorly controlled disease at one site can worsen the other.
- Explicit NSAID/aspirin-avoidance counseling for every patient with confirmed or reasonably suspected AERD, maintained until the diagnosis can be formally confirmed or excluded (see Assessment & Diagnosis and Special Populations) — genuinely actionable, pharmacist-deliverable counseling distinct from general CRS advice.
- Counsel on the practical safety implications of anosmia — a reduced ability to detect a gas leak, smoke, or spoiled food — and offer simple mitigations (working smoke/gas detectors, dated food labelling) rather than treating smell loss as a purely cosmetic complaint.
- Screen for depression/anxiety in a patient with significant, persistent olfactory loss — a genuine, under-recognized quality-of-life burden.[3]
- After FESS, ENT-directed postoperative debridement and continued saline irrigation/intranasal corticosteroid use are routine surgical aftercare, not optional add-ons.
- For a patient starting biologic therapy, set explicit expectations: benefit typically builds gradually over the first weeks to months, and the goal is disease control — reduced polyp burden, improved smell/obstruction, fewer oral corticosteroid courses and surgeries — not a guaranteed complete cure.
Special Populations
Pregnancy
Favor saline irrigation and continue an already-effective intranasal corticosteroid — minimal systemic absorption makes this class compatible with pregnancy. Avoid initiating an oral corticosteroid course where possible, particularly in the first trimester, reserving it for a genuinely needed flare or pre-operative indication with specialist input. Defer elective FESS until after delivery where clinically reasonable. Biologic therapy in pregnancy is individualized with specialist/allergy-immunology input, since pregnancy-specific safety data for dupilumab, omalizumab, and mepolizumab in CRSwNP remain limited; a patient already stable on one who becomes pregnant should not simply stop it without that discussion.[5]
Breastfeeding
Saline irrigation and intranasal corticosteroids are both considered compatible with breastfeeding. Acetaminophen is the preferred analgesic; see the AERD-specific analgesic guidance below where AERD is present. Biologic continuation in breastfeeding is an individualized decision given limited infant-exposure data for each specific agent.
Pediatrics — nasal polyps are not a routine childhood diagnosis
Unlike adenoidal hypertrophy or ordinary CRS, isolated nasal polyps in a child under about 12 are genuinely uncommon and should prompt mandatory cystic fibrosis evaluation (sweat chloride and/or CFTR genetic testing) before being managed as adult-pattern CRSwNP — one of the more important, easy-to-miss red flags in this chapter.[1] An antrochoanal polyp (see Red Flags & Refer) is also disproportionately a pediatric/young-adult presentation. Biologic therapy is not established in young children and is generally reserved for adolescents under specialist direction, following the individual agent's age-specific Health Canada authorization.
Confirmed AERD — the full management approach
Counsel explicitly on lifelong avoidance of aspirin and other cyclooxygenase-1-inhibiting NSAIDs (ibuprofen, naproxen, and similar agents) outside a supervised desensitization protocol — an inadvertent exposure can trigger a genuine acute respiratory reaction, either bronchospasm or severe nasal congestion/rhinorrhea.[9] Acetaminophen is generally well tolerated at standard doses, though very high single doses have occasionally been reported to provoke a mild reaction in a minority of patients — a practical reason to counsel standard, not maximal, dosing.[9] COX-2-selective agents (e.g., celecoxib) are tolerated by the large majority of patients with AERD, but cross-reactivity is not zero; a first dose is reasonably taken under medical guidance or after discussion with the patient's allergist rather than assumed universally safe.[9]
Aspirin desensitization, performed only in a monitored allergy/immunology setting, involves a graded oral aspirin challenge with progressively increasing doses given at timed intervals over 1 to 3 days until a target dose is tolerated, followed by daily maintenance aspirin thereafter.[9] This is a genuinely effective, guideline-supported option for reducing polyp recurrence and the need for repeat surgery, and for improving both sinus and asthma control — it should be discussed with every confirmed AERD patient rather than reserved as a last resort, and is not merely a safety maneuver to permit future NSAID use for an unrelated indication.[9][8] It is never a self-directed home therapy.
Comorbid asthma
Optimize asthma control as part of routine CRSwNP management — the relationship runs both directions, with uncontrolled polyps able to worsen asthma and vice versa. A biologic already indicated for the patient's asthma phenotype is a reasonable, efficient single-drug choice covering both diseases where eligibility for both aligns, since dupilumab, omalizumab, and mepolizumab are each also asthma biologics.
Older adults
Use particular caution with repeated oral corticosteroid courses given cumulative bone density, glycemic, and cardiovascular risk; consider bone health monitoring with recurrent courses, and maintain a lower threshold to move to biologic therapy or surgery rather than repeating oral corticosteroid courses indefinitely in this population.
Renal and hepatic impairment
Saline irrigation and intranasal corticosteroids require no adjustment. The biologic doses in this chapter are not renally or hepatically adjusted per current product monographs. Use oral corticosteroids cautiously in significant hepatic impairment.
Monitoring & Follow-Up
- Reassess 8-12 weeks after starting or intensifying intranasal-corticosteroid-and-saline therapy — confirm technique and adherence before judging response, exactly as in the Chronic Sinusitis chapter.
- Track the Nasal Polyp Score on serial ENT endoscopy as the objective measure of polyp burden and treatment response, alongside a patient-reported tool such as SNOT-22.
- On biologic therapy, formally reassess subjective and objective response at 16 weeks, and again at 1 year, per the Canadian Rhinology Working Group framework — ongoing benefit, not simply absence of harm, should be confirmed before continuing indefinitely.[2]
- Periodically reassess olfaction with a structured test where available, since patient-reported smell can lag or overstate objective improvement.
- After FESS, follow the ENT-directed postoperative debridement/surveillance schedule; continue saline irrigation and intranasal corticosteroid maintenance afterward.
- Reassess for AERD, cystic fibrosis/primary ciliary dyskinesia, or EGPA in any patient whose CRSwNP remains genuinely refractory despite an adherent, adequate trial of standard therapy.
- For a patient on maintenance aspirin after desensitization, confirm ongoing daily adherence at follow-up — stopping and later restarting maintenance aspirin can itself provoke a reaction and generally requires re-desensitization.[9]
Common Errors to Avoid
- Diagnosing or excluding CRSwNP on anterior rhinoscopy alone rather than nasal endoscopy — polyps confined to the middle meatus are easily missed.
- Treating a unilateral polyp as routine CRSwNP instead of recognizing it as a red flag needing biopsy.
- Missing nasal polyps in a child as a cystic fibrosis red flag, and instead managing them as ordinary pediatric sinus disease.
- Failing to ask specifically about NSAID/aspirin reactions in a patient with CRSwNP and asthma, and inadvertently exposing an unrecognized AERD patient to aspirin or an NSAID for an unrelated indication.
- Assuming acetaminophen and COX-2-selective NSAIDs are automatically and universally safe in confirmed AERD, rather than counseling standard dosing and, for a COX-2-selective agent, appropriate first-dose caution.
- Offering or expecting biologic therapy or surgery as an early-line option rather than reserving these for CRSwNP that remains severe despite an adequate trial of standard medical therapy.
- Using repeated oral corticosteroid courses as routine long-term CRSwNP management rather than recognizing a repeated need for them as a signal to escalate to biologic therapy or surgery.
- Assuming FESS alone is curative and stopping saline irrigation/intranasal corticosteroids afterward — polyps recur in a substantial proportion of patients without continued medical therapy.
- Requiring comorbid asthma before considering a patient for biologic therapy — the Canadian eligibility framework does not require it.
- Stopping maintenance aspirin after desensitization without recognizing that restarting it later generally requires re-desensitization.
- Promising a patient that biologic therapy or surgery will fully restore smell — meaningful improvement is expected, but established anosmia does not always completely reverse.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Intranasal Corticosteroids — High-Dose Backbone Therapy
The mainstay of therapy for CRSwNP, combined with high-volume saline irrigation. See the Chronic Sinusitis chapter for the complete class listing (fluticasone propionate, beclomethasone); the two agents below are highlighted here for their CRSwNP-specific delivery notes.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Mometasone | 2 sprays/nostril once daily | Nasal irritation/burning, epistaxis | None significant at intranasal doses | Commit to a genuine 8-12 week trial before judging response; ENT may direct an intensified regimen for polyp-predominant disease. |
| Budesonide | 2 sprays/nostril daily, or 1 spray/nostril BID | Nasal irritation/burning, epistaxis | None significant | Respule/ampule formulation can be compounded into a high-volume saline irrigation under ENT direction for greater topical deposition on polyps, particularly post-FESS. |
Oral Corticosteroids — Severe or Pre-Operative CRSwNP
Short, infrequent courses only, given cumulative systemic risk with repeated use. A repeated need for oral corticosteroids is a signal to evaluate biologic therapy or surgery, not to keep repeating the course.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisone | 0.5 mg/kg/day (up to 50 mg) PO once daily, tapered over 2-3 weeks; a shorter 5-7 day burst is reasonable for a milder flare | Hyperglycemia, insomnia, mood change, GI upset, fluid retention; adrenal suppression and reduced bone density with repeated courses | Increased hyperglycemia risk with other glucose-elevating drugs; increased GI bleed risk with NSAIDs; may reduce vaccine response | Reserve for a genuine flare or pre-operative polyp shrinkage; reassess the need for biologic therapy or surgery rather than repeating courses for recurring flares. |
Biologic Therapy — Severe, Refractory CRSwNP
Health Canada-approved as add-on therapy to an intranasal corticosteroid specifically for adults with severe CRSwNP inadequately controlled by standard medical therapy (and, per the Canadian eligibility framework, appropriate prior sinus surgery or a documented contraindication to it) — a severe/refractory-disease option, not early-line therapy. See Choose Initial Treatment for the full eligibility criteria.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Dupilumab | 600 mg SC loading dose, then 300 mg SC every 2 weeks | Injection-site reaction, conjunctivitis, eosinophilia | Avoid live vaccines during treatment | IL-4/IL-13 pathway inhibitor. SINUS-24/SINUS-52 trial evidence for reduced polyp size, sinus opacification, and symptom severity. |
| Omalizumab | Weight- and IgE-based dosing per the product monograph | Injection-site reaction; rare anaphylaxis | Avoid live vaccines during treatment | Anti-IgE mechanism. POLYP 1/POLYP 2 trial evidence; a reasonable alternative particularly with a strong allergic/atopic component. |
| Mepolizumab | 100 mg SC every 4 weeks | Injection-site reaction, headache | Avoid live vaccines during treatment | Anti-IL-5 mechanism. SYNAPSE trial evidence; a reasonable alternative particularly with a strong peripheral eosinophilia. |
Aspirin Desensitization and Maintenance — Confirmed AERD, Specialist-Directed
Performed exclusively in a monitored allergy/immunology setting — never a self-directed home therapy. Reduces polyp recurrence and improves both sinus and asthma control in confirmed AERD.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetylsalicylic acid (desensitization protocol) | Graded oral challenge with progressively increasing doses over 1-3 days to a target dose, then daily maintenance (commonly in the range of 325-650 mg twice daily), per the supervising specialist's protocol | GI upset/bleeding; the desensitization reaction itself (bronchospasm, rhinorrhea, flushing), managed only in a monitored setting | Increased bleeding risk with anticoagulants; avoid other NSAIDs during desensitization | Stopping maintenance therapy generally requires re-desensitization before restarting — confirm ongoing daily adherence at every follow-up. |
Adjunctive Leukotriene-Pathway Therapy
Weak direct evidence for CRSwNP itself — a reasonable adjunct specifically when comorbid allergic rhinitis or asthma needs treatment in its own right, and of particular mechanistic interest in AERD given its leukotriene-driven pathophysiology.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Montelukast | 10 mg PO once daily | Headache, GI upset; rare neuropsychiatric effects | Phenobarbital/rifampin may reduce montelukast levels | Consider only alongside, not instead of, saline irrigation and an intranasal corticosteroid. |
Analgesic Selection in Confirmed or Suspected AERD
A distinctly AERD-specific counseling table: which common analgesics are generally safe, generally avoided, and how to handle uncertainty. Confirm the patient's AERD status before applying these distinctions to a patient whose CRSwNP-and-asthma history has not been specifically screened (see Assessment & Diagnosis).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetaminophen | Standard doses; avoid very high single doses | Well tolerated by most patients with AERD | Standard acetaminophen interaction profile | Generally preferred first-line analgesic in confirmed AERD; a minority of patients report a mild reaction at high single doses, so counsel standard rather than maximal dosing. |
| Celecoxib | Per standard product dosing | GI upset, fluid retention; cardiovascular risk at high doses/prolonged use, as with any NSAID | Standard NSAID interaction profile; avoid combining with another NSAID | COX-2 selective; tolerated by the large majority of patients with AERD, but cross-reactivity is not zero — a first dose is reasonably taken under medical guidance or after discussion with the patient's allergist. |
| Ibuprofen | Not used outside a supervised desensitization protocol | A classic AERD trigger — nasal congestion/rhinorrhea and/or bronchospasm via COX-1 inhibition | Standard NSAID interaction profile | Do not dispense or recommend for an unrelated indication without first confirming the patient's AERD status. |
| Naproxen | Not used outside a supervised desensitization protocol | A classic AERD trigger — nasal congestion/rhinorrhea and/or bronchospasm via COX-1 inhibition | Standard NSAID interaction profile | Same COX-1-mediated class risk as ibuprofen and other non-selective NSAIDs in confirmed AERD. |
References
- European Position Paper on Rhinosinusitis and Nasal Polyps 2020 — Rhinology (Fokkens WJ, Lund VJ, Hopkins C, et al.). Rhinology 2020;58(Suppl S29):1-464
- Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis — Journal of Otolaryngology - Head & Neck Surgery (Thamboo A, Kilty S, Witterick I, Chan Y, Chin CJ, Janjua A, et al.). J Otolaryngol Head Neck Surg 2021;50:15
- EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care — Allergy (Hellings PW, Alobid I, Anselmo-Lima WT, Bernal-Sprekelsen M, et al.). Allergy 2024;79(5):1123-1133
- Evaluation of methods for endoscopic staging of nasal polyposis — Acta Oto-Laryngologica (Johansson L, Åkerlund A, Holmberg K, Melén I, Bende M). Acta Otolaryngol 2000;120(1):72-76
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials — The Lancet (Bachert C, Han JK, Desrosiers M, et al.). Lancet 2019;394(10209):1638-1650
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials — Journal of Allergy and Clinical Immunology (Gevaert P, Omachi TA, Corren J, et al.). J Allergy Clin Immunol 2020;146(3):595-605
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial — The Lancet Respiratory Medicine (Han JK, Bachert C, Fokkens W, et al.). Lancet Respir Med 2021;9(10):1141-1153
- Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease — Journal of Allergy and Clinical Immunology (Haque R, White AA, Jackson DJ, Hopkins C). J Allergy Clin Immunol 2021;148(2):283-291
- The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology — Journal of Allergy and Clinical Immunology (Stevens WW, Jerschow E, Baptist AP, et al.). J Allergy Clin Immunol 2021;147(3):827-844
- Clinical Practice Guideline: Surgical Management of Chronic Rhinosinusitis — Otolaryngology-Head and Neck Surgery, American Academy of Otolaryngology-Head and Neck Surgery Foundation (Shin JJ, Wilson M, McKenna M, et al.). Otolaryngol Head Neck Surg 2025;172(S2):S1-S47
- Canadian multidisciplinary expert consensus on the use of biologics in upper airways: a Delphi study — Journal of Otolaryngology - Head & Neck Surgery (Thamboo AV, Lee M, Bhutani M, et al.). J Otolaryngol Head Neck Surg 2023;52:30
- Canadian clinical practice guidelines for acute and chronic rhinosinusitis — Allergy, Asthma & Clinical Immunology (Desrosiers M, Evans GA, Keith PK, et al.). Allergy Asthma Clin Immunol 2011;7(1):2
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.